Patents by Inventor Philip Hass

Philip Hass has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PREVENTION AND TREATMENT OF COMPLEMENT-ASSOCIATED EYE CONDITIONS
    Publication number: 20180079826
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Application
    Filed: November 29, 2017
    Publication date: March 22, 2018
    Applicant: Genentech, Inc.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, Micah Steffek, Christian Weismann, Menno Van Lookeren Campagne
  • PREVENTION AND TREATMENT OF COMPLEMENT-ASSOCIATED EYE CONDITIONS
    Publication number: 20160272726
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Application
    Filed: February 3, 2016
    Publication date: September 22, 2016
    Inventors: Philip HASS, Yin Jianping, Kenneth Katschke, JR., Micah Steffek, Christian Weismann, Menno Van Lookeren Campagne
  • PREVENTION AND TREATMENT OF COMPLEMENT-ASSOCIATED EYE CONDITIONS
    Publication number: 20130302333
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Application
    Filed: June 27, 2013
    Publication date: November 14, 2013
    Applicant: GENENTECH, INC.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, JR., Micah Steffek, Christian Weismann, Menno Van Lookeren Campagne
  • Prevention and treatment of complement-associated eye conditions
    Patent number: 8497094
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: July 30, 2013
    Assignee: Genentech, Inc.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, Jr., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • PREVENTION AND TREATMENT OF COMPLEMENT-ASSOCIATED EYE CONDITIONS
    Publication number: 20130052685
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Application
    Filed: July 20, 2012
    Publication date: February 28, 2013
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, JR., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • Prevention and treatment of complement-associated eye conditions
    Patent number: 8268310
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: September 18, 2012
    Assignee: Genentech, Inc.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, Jr., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • PREVENTION AND TREATMENT OF COMPLEMENT-ASSOCIATED EYE CONDITIONS
    Publication number: 20110282034
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Application
    Filed: July 22, 2011
    Publication date: November 17, 2011
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, JR., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • Prevention and treatment of complement-associated eye conditions
    Patent number: 8007791
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: August 30, 2011
    Assignee: Genentech, Inc.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, Jr., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • Crystal structure of CRIg and C3b:CRIg complex
    Patent number: 7930109
    Abstract: The present invention concerns determination of the crystal structure of the macrophage specific receptor, CRIg (earlier referred to as STIgMA), and its complex with the C3b and C3c subunits of complement C3 (C3b:CRIg and C3c:CRIg complexes). The invention further concerns the use of the crystal structure of CRIg or the C3b:CRIg complex to screen for and identify molecules structurally and/or functionally related to CRIg, including CRIg agonists and antagonists.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: April 19, 2011
    Assignee: Genentech, Inc.
    Inventors: Philip Hass, Jianping Yin, Kenneth Katschke, Micah Steffek, Menno Van Lookeren Campagne, Christian Wiesmann
  • Crystal Structure of CRIg and C3B:CRIg Complex
    Publication number: 20100291694
    Abstract: The present invention concerns determination of the crystal structure of the macrophage specific receptor, CRIg (earlier referred to as STIgMA), and its complex with the C3b and C3c subunits of complement C3 (C3b:CRIg and C3c:CRIg complexes). The invention further concerns the use of the crystal structure of CRIg or the C3b:CRIg complex to screen for and identify molecules structurally and/or functionally related to CRIg, including CRIg agonists and antagonists.
    Type: Application
    Filed: December 14, 2009
    Publication date: November 18, 2010
    Inventors: Philip Hass, Jianping Yin, Kenneth Katschke, Micah Steffek, Menno Van Lookeren Campagne, Christian Wiesmann
  • Crystal structure of CRIg and C3b:CRIg complex
    Patent number: 7776573
    Abstract: The present invention concerns determination of the crystal structure of the macrophage specific receptor, CRIg (earlier referred to as STIgMA), and its complex with the C3b and C3c subunits of complement C3 (C3b:CRIg and C3c:CRIg complexes). The invention further concerns the use of the crystal structure of CRIg or the C3b:CRIg complex to screen for and identify molecules structurally and/or functionally related to CRIg, including CRIg agonists and antagonists.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: August 17, 2010
    Assignee: Genentech, Inc.
    Inventors: Philip Hass, Jianping Yin, Kenneth Katschke, Micah Steffek, Menno Van Lookeren Campagne, Christian Wiesmann
  • Prevention and treatment of complement-associated eye conditions
    Publication number: 20090181017
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Application
    Filed: May 22, 2008
    Publication date: July 16, 2009
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, JR., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • Crystal structure of CRIg and C3b:CRIg complex
    Publication number: 20080045697
    Abstract: The present invention concerns determination of the crystal structure of the macrophage specific receptor, CRIg (earlier referred to as STIgMA), and its complex with the C3b and C3c subunits of complement C3 (C3b:CRIg and C3c:CRIg complexes). The invention further concerns the use of the crystal structure of CRIg or the C3b:CRIg complex to screen for and identify molecules structurally and/or functionally related to CRIg, including CRIg agonists and antagonists.
    Type: Application
    Filed: May 30, 2007
    Publication date: February 21, 2008
    Inventors: Philip Hass, Jianping Yin, Kenneth Katschke, Micah Steffek, Menno Campagne, Christian Wiesmann
  • IL-17A/F heterologous polypeptides and therapeutic uses thereof
    Publication number: 20070160576
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: November 29, 2006
    Publication date: July 12, 2007
    Applicant: Genentech, Inc.
    Inventors: David Arnott, Mercedesz Balazs, Nico Ghilardi, Austin Gurney, Philip Hass, Sarah Hymowitz, James Lee, Wenjun Ouyang, Melissa Starovasnik, Yan Wu
  • IL-17A/F heterologous polypeptides and therapeutic uses thereof
    Publication number: 20060270003
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: June 2, 2004
    Publication date: November 30, 2006
    Inventors: David Arnott, Austin Gurney, Philip Hass, James Lee, Yan Wu
  • Human anti-factor IX/IXa antibodies
    Publication number: 20060193851
    Abstract: The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting the activation of FIX and inhibiting FIX/IXa dependent coagulation.
    Type: Application
    Filed: March 31, 2006
    Publication date: August 31, 2006
    Inventors: Camellia Adams, Brigitte Devaux, Dan Eaton, Philip Hass, J. Judice, Daniel Kirchhofer, Shelley Suggett
  • HUMAN ANTI-FACTOR IX/IXA ANTIBODIES
    Publication number: 20060088534
    Abstract: The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting the activation of FIX and inhibiting FIX/IXa dependent coagulation.
    Type: Application
    Filed: July 8, 2003
    Publication date: April 27, 2006
    Inventors: Camellia Adams, Brigitte Devaux, Dan Eaton, Philip Hass, J. Judice, Daniel Kirchhofer, Shelley Suggett